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Abstract
Background:  The  LAT  gene encodes an intracellular adaptor protein that links cell-surface
receptor engagement to numerous downstream signalling events, and thereby plays an integral role
in the function of cell types that express the gene, including T cells, mast cells, natural killer cells,
and platelets. To date, the mechanisms responsible for the transcriptional regulation of this gene
have not been investigated.
Results: In this study we have mapped the transcriptional start sites for the human LAT gene and
localized the 5' and 3' boundaries of the proximal promoter. We find that the promoter contains
both positive and negative regulatory regions, and that two binding sites for the Ets family of
transcription factors have a strong, positive effect on gene expression. Each site binds the Ets family
member Elf-1, and overexpression of Elf-1 augments LAT promoter activity. The promoter also
contains a Runx binding site adjacent to one of the Ets sites. This site, which is shown to bind Runx-
1, has an inhibitory effect on gene expression. Finally, data is also presented indicating that the
identified promoter may regulate cell-type specific expression.
Conclusion: Collectively, these results provide the first insights into the transcriptional regulation
of the LAT gene, including the discovery that the Ets transcription factor Elf-1 may play a central
role in its expression.
Background
The LAT gene encodes a 36–38 kD transmembrane pro-
tein that connects various cell surface receptors to down-
stream signaling events. Following receptor engagement,
LAT becomes heavily tyrosine phosphorylated and subse-
quently binds a number of proteins containing SH2
domains, including members of the Grb2 family (Grb2,
Gads, Grap) and phospholipase C-γ (PLC-γ) [1,2]. The
interaction of Grb2, PLC-γ and other proteins with LAT
facilitates their activation and leads to additional bio-
chemical events required for a productive cellular
response, including activation of the Ras-MAPK signaling
pathway and an elevation in intracellular calcium levels
[1,2].
One receptor type whose engagement results in LAT tyro-
sine phosphorylation is the T cell receptor (TCR) [3,4].
The essential role of LAT in TCR signaling has been
revealed through the study of mutant Jurkat T cell lines
that fail to express the LAT gene [5,6]. These LAT-deficient
T cells display a number of signaling defects that prevent
T cell activation and effector cell function. An analysis of
Published: 07 February 2006
BMC Molecular Biology 2006, 7:4 doi:10.1186/1471-2199-7-4
Received: 28 November 2005
Accepted: 07 February 2006
This article is available from: http://www.biomedcentral.com/1471-2199/7/4
© 2006 Finco et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Molecular Biology 2006, 7:4 http://www.biomedcentral.com/1471-2199/7/4
Page 2 of 14
(page number not for citation purposes)
LAT-deficient mice has also shown that the LAT protein is
necessary for T cell maturation within the thymus [7]. In
addition to its requirement for T cell development and
function, LAT has important roles in other cell-types. For
example, LAT is required for mast cell activation following
engagement of the high affinity receptor for immunoglob-
ulin E, for Natural Killer (NK) cell-mediated cytotoxicity,
and for collagen, collagen-related peptide, and convulxin-
mediated activation of platelets [8-12]. Moreover, engage-
ment of the pre-B cell receptor on developing B cells
induces LAT tyrosine phosphorylation, an event that may
contribute to B cell differentiation [13-15].
The identified role of LAT in these cell-types is reflective of
its expression pattern. LAT RNA and/or protein has been
detected in the thymus, spleen, and peripheral blood cells
but is absent in the colon, brain, small intestine, ovary,
testis, prostate, kidney, skeletal muscle, and liver [3,4,16].
Examination of specific cell-types indicates that LAT gene
expression is restricted to a subset of cell-types generated
during hematopoiesis, namely T cells, mast cells, platelets,
and NK cells [3,4,16]. LAT is also expressed at low levels
during the early stages of B cell development and is subse-
quently down-regulated prior to B cell maturation
[14,15].
To date, the means by which the LAT gene is transcription-
ally regulated has not been investigated. In the present
work, we have mapped the transcriptional start sites for
the human LAT gene and localized the proximal promoter
region to approximately 800 bp extending upstream of
the translation start site. Within the promoter, we have
identified a negative regulatory region and two Ets bind-
ing sites that are bound by the Elf-1 transcription factor.
Mutation of these Ets sites significantly reduces promoter
activity, and consistent with these findings, overexpres-
sion of Elf-1 potently enhances LAT promoter function. A
Runx binding site is also identified that binds Runx-1, and
which when mutated results in an increase in LAT pro-
moter activity. The data presented also suggests that the
identified promoter region may mediate cell-type specific
expression of the LAT gene. Collectively, these results pro-
vide the first insights into the transcriptional regulation of
the LAT gene, which encodes an essential adaptor protein
linking cell-surface receptors to critical downstream sign-
aling events.
Results
The LAT gene contains multiple transcription start sites
As an initial step in the identification and characterization
of the LAT promoter, we mapped the transcription start
site(s) for the human LAT gene using RNA ligase-medi-
ated rapid amplification of cDNA ends (RLM-RACE) and
poly(A) RNA isolated from Jurkat T cells or human thy-
mus. The products of RLM-RACE, which are only derived
from RNA transcripts extending to the terminal 5' cap
structure [17,18], were ligated into the pBluescript® vector
and 15 of the resulting clones from each source of RNA
were sequenced. The results indicate that the LAT gene
possesses multiple transcription start sites that lie in a
region spanning roughly 75 bp and located between 250
to 335 bp upstream of the translation start site (Fig. 1).
The transcription start sites mapped to the same general
region in Jurkat T cells and human thymus, and in many
cases the same sites were utilized. Analysis of the DNA
sequence surrounding the transcription start sites revealed
that the region is G/C-rich but lacks consensus sites for
either a TATA box or initiator elements. Similar to this sit-
A 450 bp region of the proximal LAT promoter Figure 1
A 450 bp region of the proximal LAT promoter. The 
DNA sequence extending 450 bp upstream of the translation 
start site for the human gene and the homologous region 
from the mouse genome are shown. Bases conserved 
between the human and mouse are shaded. The 'A' nucle-
otide in the translation start site ATG codon (underlined) for 
the human sequence has been designated as +1 in this study. 
The transcription start sites identified for the endogenous 
LAT gene in Jurkat T cells have a '● ' above the site, those 
mapped using RNA isolated from human thymus have a '■ ' 
above the site, and those that were identified in both Jurkat 
cells and thymus are indicated with a '' above the site. 
Potential binding sites for transcription factors of the Ets and 
Runx family are indicated with a bar above the site and the 
transcription factor name. Specific point mutations intro-
duced into the -1000 to -1 promoter fragment are indicated 
below each site.BMC Molecular Biology 2006, 7:4 http://www.biomedcentral.com/1471-2199/7/4
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uation, it has been observed that other G/C-rich promot-
ers which lack a TATA box or initiator elements also
possess multiple transcription start sites that span regions
of 75 bp or more [19].
The LAT promoter extends 800 bp upstream of the 
translation start site
To ascertain whether regions 5' and 3' of the transcription
start sites possess promoter activity, a DNA fragment
extending 1200 bp upstream from the translation start site
was amplified by PCR and inserted adjacent to the firefly
luciferase gene in the pGL3-basic vector. Of note, in this
study the 'A' nucleotide of the translation start site ATG
codon has been designated +1. Thus, the transcription
start sites lie in the region from -335 to -250 and the 1200
bp fragment extends from -1200 to -1. Transient transfec-
tion into Jurkat T cells with the luciferase reporter con-
struct containing the -1200 to -1 DNA fragment resulted
in a greater than 10-fold increase in luciferase activity rel-
ative to the empty, promoterless pGL3-basic vector, dem-
onstrating that this DNA fragment contains significant
promoter activity (Fig. 2A). In order to more precisely
map the boundaries of the promoter, sequential 5' and 3'
deletions of 200 bp were introduced and the effect on pro-
moter activity was determined in Jurkat cells. Deletion of
the region from -1200 to -800 did not have an appreciable
effect on promoter activity. However, deletion of the
region from -800 to -600 resulted in a decrease in pro-
moter activity, and a further decrease was observed when
the region from -600 to -400 was removed. Finally, when
the -400 to -200 region was deleted, promoter activity
dropped to background levels (Fig. 2A).
Surprisingly, when the 3' 200 bp was removed from the -
1000 to -1 promoter fragment (-1000 to -200), a substan-
tial increase in promoter activity occurred (Fig. 2B). How-
ever, removal of an additional 200 bp from the 3' end (-
1000 to -400) completely abrogated promoter activity
(Fig. 2B). This latter result is most likely a consequence of
eliminating all the transcription start sites (see Fig. 1). In
summary, these results indicate that the proximal pro-
moter for the LAT gene lies in a region extending from -
800 to -1 relative to the translation start site, with the
region from -800 to -200 having an overall stimulatory
effect on promoter activity while the region from -200 to
-1 has an inhibitory effect.
In this initial study of the LAT promoter, we chose to focus
on the region spanning from -600 to -200 since it con-
tained a significant portion of promoter activity (Fig. 2A).
To more precisely map the positive regulatory elements
within this region, a series of sequential 50 bp deletions
from the 5' end of the -600 to -1 fragment were created
and the resultant promoter activity of each DNA fragment
was determined in Jurkat T cells. As shown in Fig. 2C,
deletion of the region from -600 to -450 did not result in
a significant loss in promoter function. In contrast, dele-
tion of the region from -450 to -350 reduced promoter
activity to background levels (Fig. 2C). These results indi-
cate that the region spanning from -450 to -350 contains
a substantial portion of the positive regulatory elements
mediating transcription of the human LAT gene. Consist-
ent with these data, a DNA fragment spanning from -450
to -300, which contains the -450 to -350 stimulatory
region and a number of transcription start sites found
between -350 to -300, displayed robust promoter activity
(Fig. 2D).
Linker scanning mutagenesis of the -450 to -350 region 
within the LAT promoter
Linker scanning mutagenesis throughout the -450 to -350
region, conducted by introducing sequential 10 bp muta-
Mapping the 5' and 3' boundaries of the LAT promoter Figure 2
Mapping the 5' and 3' boundaries of the LAT pro-
moter. A.-D. Jurkat T cells were transiently transfected 
with a pGL3-basic firefly luciferase reporter vector contain-
ing various DNA fragments extending upstream of the trans-
lation start site for the human LAT gene. Cells were also co-
transfected with the internal control pRL-TK Renilla luci-
ferase plasmid. Following incubation, cells were harvested, 
luciferase activity was quantitiated and after normalization of 
each sample based on Renilla luciferase activity, the fold acti-
vation relative to the empty pGL3-basic vector was calcu-
lated. Results presented are the average fold induction and 
the standard error of the mean (s.e.m.) from three or more 
independent experiments. For each graph, the human LAT 
promoter fragments inserted into pGL3-basic are shown 
schematically on the left. Arrows depict the two clusters of 
transcription start sites for the LAT gene.
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tions containing a NotI restriction site sequence, was per-
formed with the -1000 to -1 promoter fragment and the
effects on promoter activity were tested in Jurkat T cells
(Fig. 3A and 3B). Each 10 bp mutation resulted in a
decrease in promoter activity, with the most dramatic
reduction occurring when the region from -390 to -350
was altered (Fig. 3B).
To ensure that the effects observed in the linker scanning
mutagenesis experiments were not an artifact of the intro-
duced sequence, we also constructed an additional set of
linker scanning mutations throughout the -400 to -350
region, sequentially mutating the same 10 bp segments
except introducing a sequence containing the NheI restric-
tion site. Transient transfection of these reporter con-
structs in Jurkat T cells yielded results similar to those
obtained in Fig. 3B except for the region spanning from -
380 to -371, which when mutated in this latter set of
experiments yielded only a ~50% decrease in promoter
function (data not shown).
Collectively, the data from linker scanning mutagenesis
indicates that the entire region from -450 to -350 is
required for optimal LAT promoter activity in Jurkat T
cells, with DNA sequences from -390 to -350 having the
most prominent role.
Two Ets sites are required for LAT promoter activity
Analysis of the -450 to -350 region using a variety of tran-
scription factor binding site databases, including TRANS-
FAC®, JASPAR, and MatInspector [20-22], revealed a
number of possible regulatory elements, including two
sites that contain the core binding sequence (5'-TTCC-3')
for the Ets family of transcription factors (see Fig. 1) [23-
26]. These potential Ets sites, which lie within the critical
-390 to -350 region, were of particular interest in light of
the well-documented role Ets transcription factors play in
the development and function of T cells and other cell
types that express the LAT gene [24-26].
To determine the function of each putative Ets site in the
regulation of the LAT  promoter, point mutations were
introduced into each of these sites (see Fig. 1) in the con-
text of the -1000 to -1 promoter fragment and the effect of
each mutation was determined in Jurkat T cells. When
either Ets site was mutated, a significant decrease in pro-
moter activity was observed (Fig. 4). Furthermore, simul-
taneous deletion of both Ets sites resulted in a level of
promoter activity less than when either site alone was
mutated. These data demonstrate that both putative Ets
sites have a strong, positive effect on LAT promoter func-
tion in T cells.
Both Ets sites bind Elf-1, a member of the Ets transcription 
factor family
Electrophoretic mobility shift assays (EMSAs) were used
to identify protein complexes that specifically bind each
of the putative Ets sites. 32P labeled DNA probes encom-
passing each Ets site were incubated with nuclear extracts
from Jurkat T cells and then analyzed by nondenaturing
polyacrylamide gel electrophoresis and autoradiography.
Two major complexes were detected binding to the Ets site
centered at -360 (Fig. 5A). One of these complexes was
competed for with a 100-fold excess of unlabeled wild-
type probe (self wt) but was not competed for when the
Ets site was mutated (self mutEts), demonstrating that this
complex specifically interacted with the Ets site. Of note,
the mutant probe used in these competition experiments
contained the same bp changes as those introduced into
the Ets site in the promoter construct used in transient
transfections.
Additional competition experiments were performed with
an unlabeled probe containing a consensus Ets site (cons.
wt) or the same probe except that the Ets site was dis-
rupted by a point mutation (cons. mutEts) (Fig. 5A). The
loss of binding in the presence of the consensus wild-type
Ets sequence but not with the mutated sequence suggested
that the specific complex contains members of the Ets
family of transcription factors. In an effort to identify the
particular Ets family members capable of binding the -360
Ets site, we performed antibody supershift experiments.
The human genome contains 27 genes that encode mem-
bers of the Ets family of transcription factors, 16 of which
have been shown to be expressed in Jurkat cells [27]. We
chose to focus on Ets-1, Ets-2, Elf-1, and Fli-1, Ets family
members implicated in the regulation of gene expression
in T cells and other cell types that express the LAT gene
[23-26]. Although addition of antibodies to Ets-2 or Fli-1
had no discernible effect, in the presence of the Elf-1 anti-
body a significant decrease in the intensity of the specific
complex was observed, and upon longer exposure of the
gel, supershifted complexes were detected (Fig. 5B and
5C). It was also evident upon addition of the Elf-1 anti-
body that the specific complex contains at least two distin-
guishable bands, one of which appears unaffected by the
Elf-1 antibody (Fig. 5B). Finally, in the presence of the Ets-
1 antibody, a novel slower mobility band appeared.
Although the appearance of this band was not accompa-
nied by an appreciable decrease in the intensity of the spe-
cific complex, it is known that antibodies to Ets-1 can
enhance its DNA binding capability, and thus we can not
presently exclude the possibility that Ets-1 may also bind
to this site in the LAT promoter. In summary, these results
indicate that the -360 Ets site in the LAT promoter is capa-
ble of binding the Ets transcription factor Elf-1, and also
possibly Ets-1.BMC Molecular Biology 2006, 7:4 http://www.biomedcentral.com/1471-2199/7/4
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When the Ets site centered at -390 was examined by
EMSA, three complexes were detected (Fig. 6A). Two of
these complexes were competed for with a 100-fold excess
of unlabeled wild-type probe, but not when the Ets site
was mutated, demonstrating that the binding of these
complexes required an intact Ets site. When the consensus
Ets site was used in competition experiments, the more
prominent specific complex was competed for while the
less prominent one was unaffected (Fig. 6A), suggesting
that the more prominent complex contains Ets family
members. The composition of the less prominent com-
plex is uncertain at this time but may contain a transcrip-
tion factor that binds to a site that overlaps the Ets site. In
supershift experiments, addition of antibodies to Ets-1,
Ets-2, and Fli-1 had no appreciable effect on the specific
complexes, but when the Elf-1 antibody was added to the
binding reaction an almost complete loss of the most
prominent complex was observed, and this was accompa-
nied by the appearance of slower mobility, supershifted
bands (Fig. 6B). These data demonstrate that Elf-1 is capa-
ble of binding both Ets sites in the LAT promoter.
Activation of the LAT promoter by overexpression of Elf-1
To further explore the potential role of Elf-1 in the regula-
tion of LAT gene expression, overexpression studies were
conducted. Preliminary experiments were performed in
Jurkat T cells and failed to reveal an effect of Elf-1 overex-
pression on LAT promoter activity (data not shown), a
result likely attributable to the high endogenous levels of
this transcription factor in these cells [27,28]. We there-
fore used HeLa cells for these experiments, which in con-
trast to Jurkat T cells express low to undetectable levels of
the Elf-1 [27-29]. Overexpression of Elf-1 in HeLa cells
resulted in a greater than 10-fold increase in LAT pro-
moter activity (Fig. 7). Of note, identical results were
obtained when either the -400 to -1 promoter fragment
Linker scanning mutagenesis of the -450 to -351 region of the LAT promoter Figure 3
Linker scanning mutagenesis of the -450 to -351 region of the LAT promoter. Sequential 10 bp mutations were 
introduced throughout the -450 to -351 region in the context of the -1000 to -1 promoter fragment and the effects on pro-
moter activity were determined in Jurkat T cells. A. The wild-type promoter sequence from -450 to -351 is shown on top. The 
lower strand depicts each 10 bp change, which incorporates a Not I restriction site (GCGGCCGC) plus one flanking nucleotide 
on each side. Base pair numbering is according to the translation start site, which was designated +1. B. Promoter activity for 
each linker scanning mutant was determined following transient transfection into Jurkat T cells. Following normalization of 
each sample based on the activity of co-transfected control pRL-TK plasmid encoding Renilla luciferase, the fold activation rela-
tive to empty pGL3-basic was calculated. The graph depicts the average fold activation and s.e.m. from three or more inde-
pendent experiments.
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(Fig. 7) or the -1000 to -1 promoter fragment (data not
shown) were used. To determine whether the observed
activation by Elf-1 occurred through the Ets sites centered
at -360 and -390, Elf-1 was overexpressed in the presence
of the promoter construct containing point mutations in
both these sites. Mutation of the Ets sites resulted in dra-
matic decrease in the ability of Elf-1 to stimulate promoter
function (Fig. 7), results that clearly demonstrate Elf-1 can
stimulate gene expression through both of the Ets sites in
the LAT promoter.
Role of the LAT promoter in cell-type specific expression
The LAT gene is expressed in T cells, NK cells, mast cells,
platelets, and developing B cells but not in other cells
types [3,4,16] To explore the potential role of the LAT pro-
moter in mediating cell-type specific gene expression, we
investigated promoter activity in various cell-types that
either do or do not express the endogenous LAT gene. In
addition to Jurkat T cells, the RBL-2H3 mast cell line has
been shown to express the endogenous LAT gene while
the HeLa epithelial cell line, the 70Z pre-B cell line, and
the Raji mature B cell line do not [3,15]. Reporter vectors
containing LAT promoter fragments of various lengths
were transfected into each of these cell-types and follow-
ing incubation the cells were harvested and promoter
activity quantitated.
In addition to Jurkat cells, the -1000 to -1 LAT promoter
fragment displayed significant activity in RBL-2H3 and
HeLa cells but was relatively inactive in the 70Z and Raji
B cell lines (fig. 8A). Experiments were also conducted in
each cell line using the pGL3-control vector which con-
tains the SV40 promoter and enhancer. The average fold
activation for the pGL3-control vector was 50.1 for 70Z,
245.2 for Raji, 110.3 for RBL-2H3, and 300.6 for HeLa,
indicating that the lack of appreciable LAT promoter func-
tion in 70Z and Raji cell lines is not a consequence of low
transfection efficiencies. These data suggest that the lack of
promoter activity in 70Z and Raji cells may explain why
the endogenous LAT gene is not expressed in these cell-
types. However, additional means of inhibiting LAT gene
expression likely exist since the promoter retained activity
HeLa cells, another cell-type that fails to express the
endogenous LAT gene.
In contrast to results obtained in Jurkat T cells, a promoter
fragment spanning from -400 to -1 was unable to support
gene expression in RBL-2H3 cells (Fig. 8A). This result
implies that this region of the promoter may operate dif-
ferently in these two cells-types, and it was conceivable
that the Ets sites located at -360 and -390 do not contrib-
ute to LAT promoter activity in mast cells. In order to
determine the role of the Ets sites in mast cells, we tested
the activity of the -1000 to -1 promoter fragment in the
absence or presence of mutations in each site. Our results
found that mutation of either Ets site caused a reduction
in promoter activity, and a further decrease was seen when
both Ets sites were mutated (Fig. 8B). Thus, the Ets sites
centered at -360 and -390 are required for LAT promoter
function in both Jurkat T cells and RBL-2H3 mast cells.
We also explored whether the inhibitory region spanning
from -200 to -1 may be more active in mast cells since this
could also explain why the -400 to -1 region was unable
to support gene expression in RBL-2H3 cells. When the -
1000 to -200 promoter construct was transfected into
RBL-2H3 cells, promoter activity increased over 6-fold rel-
ative to the -1000 to -1 construct (Fig. 8C). When similar
experiments were conducted in Jurkat cells, an approxi-
mately 3-fold increase was observed (Fig. 2B). Thus, the
Effect of mutating the Ets sites within the LAT promoter Figure 4
Effect of mutating the Ets sites within the LAT pro-
moter. Site-directed mutagenesis was used to mutate the 
Ets site centered at -360 (mutEts -360), the Ets site centered 
at -390 (mutEts -390), or both Ets sites (mutEts -360/-390). 
Mutations were introduced into the -1000 to -1 promoter 
fragment within the pGL3-basic vector. Specific base pair 
changes are shown in Fig. 1. Reporter plasmids were tran-
siently transfected into Jurkat T cells and fold activation was 
determined as previously described. The results depict the 
average fold induction and s.e.m. from three or more inde-
pendent experiments.
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greater suppressive effect of the -200 to -1 region on LAT
promoter activity in RBL-2H3 cells may provide one
explanation why the -400 to -1 region lacks activity in this
cell line.
The LAT promoter contains a potential Runx binding site 
adjacent to the Ets site centered at -360
Alignment of the human LAT promoter sequence with the
region upstream of the translation start site for the mouse
LAT gene revealed that the Ets sites are 100% conserved
between the two species. Interestingly, sequences adjacent
to the Ets sites are also conserved, and close inspection of
the region 5' of the Ets site centered at -360 revealed a
potential binding site for the Runx family of transcription
factors. The Runx family, also called CBFα, AML, or
PEBP2, consists of three members: Runx-1, -2, and -3
[30,31]. These transcription factors contain a conserved
128 amino acid DNA binding domain that interacts with
the consensus sequence 5'-ACCPuCA-3', and they can
either activate or repress gene expression depending on
the context of the specific promoter or enhancer [30,31].
Interestingly, in a number of instances Runx and Ets bind-
ing sites have been found adjacent to one another in gene
regulatory regions. Moreover, it has been shown that one
Runx family member, Runx-1, can physically interact with
certain Ets proteins, resulting in cooperative DNA binding
and thereby facilitating the activation of gene expression
[30,32-38]. It was therefore conceivable that in a manner
similar to other regulatory regions, Runx-1 and Ets pro-
teins cooperatively interact at the LAT promoter to acti-
vate gene expression.
As a first step in testing this possibility, EMSA was used to
determine if Runx-1 could bind to the putative Runx site
in the LAT promoter. In these experiments a 32P labeled
probe encompassing both the Runx site and the adjacent
Ets site at -360 was used, in contrast to results shown in
Fig. 5 in which case the 32P labelled probe contained the
Ets site but not the Runx site. In the presence of Jurkat
nuclear extracts, a complex formed that contained a dif-
fuse band that extended above and below a more defined
central band (Fig. 9A). Both the diffuse and central band
were effectively competed for by an excess of unlabeled
wild-type probe. When the unlabeled competitor con-
tained a mutation in the Ets site, the diffuse band was
competed for but the more defined central band was not.
Conversely, when the unlabeled competitor contained a
mutation in the Runx site, the central band was competed
for but not the more diffuse band. (Fig. 8A). Finally, when
the unlabeled competitor contained a mutation in both
the Runx and Ets sites, no bands were competed. Taken
together, these results demonstrate that the diffuse band
represents proteins specifically interacting with the Runx
site while the more defined central band represents pro-
teins specifically binding to the Ets site. Of note, the
prominent central band that remained in the presence of
the competitor containing a mutation in the Ets site could
be supershifted with an antibody to Elf-1 (Fig. 9B), which
is consistent with our earlier data identifying Elf-1 as the
major Ets family member binding to this site.
To determine whether the diffuse band may contain
Runx-1, the member of the Runx family shown to cooper-
ate with Ets proteins, we performed supershift assays. The
addition of the Runx-1 antibody to the binding reaction
The transcription factor Elf-1 binds to the -360 Ets site in the  LAT promoter Figure 5
The transcription factor Elf-1 binds to the -360 Ets 
site in the LAT promoter. A. A DNA probe encompass-
ing the Ets site centered at -360 (-360 Ets wt) was labeled 
with 32P and incubated with nuclear extracts from Jurkat T 
cells in the absence or presence of 100-fold molar excess of 
competitor DNA. Samples were subsequently loaded onto a 
nondenaturing polyacrylamide gel, electrophoresed, and then 
subjected to autoradiography. For competition experiments, 
the unlabeled competitor DNA was the same sequence as 
that of the probe (self wt), the same sequence as the probe 
except containing point mutations within the Ets site (self 
mutEts), the consensus sequence for Ets family members 
(cons. wt) or the consensus sequence except for point muta-
tions within the Ets site (cons. mutEts). The arrow indicates 
the specifically bound complex. B. Experiments were con-
ducted as in Fig. 5A except that the indicated antibody was 
added in place of competitor DNA. C. A longer exposure of 
the lane containing the Elf-1 antibody. The supershifted com-
plexes are indicated with arrows.
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caused a loss of the diffuse band and the appearance of a
supershifted complex (Fig. 9C). Thus, the identified Runx
site in the LAT promoter is capable of binding Runx-1. To
investigate the role of the Runx site in LAT promoter func-
tion, we introduced a point mutation within the putative
Runx site in the context of the -1000 to -1 promoter con-
struct and tested its activity in both Jurkat and RBL-2H3
cells. In contrast to our expectations, mutation of the
Runx site resulted in an increase in LAT promoter function
in both Jurkat and RBL-2H3 cells (Fig. 9D), implying that
this site has an inhibitory effect on LAT promoter func-
tion.
Discussion
This is the first study to examine the mechanisms regulat-
ing transcription of the human LAT gene. The data pre-
sented indicates that the gene contains numerous
transcription start sites and that the proximal promoter
extends approximately 800 bp upstream of the translation
start site. Within the promoter we identified two Ets sites
which when mutated dramatically reduced transcriptional
activity. Both Ets sites were shown to bind Elf-1, and con-
sistent with this finding, promoter activity was signifi-
cantly augmented following Elf-1 overexpression. We also
identified a binding site for Runx-1 that appears to sup-
press promoter activity. Finally, the absence of apprecia-
ble LAT promoter activity in 70Z and Raji B cell lines may
contribute to the cell-type specific expression of this gene.
Our results demonstrate that deletion of the region from -
200 to -1 leads to a 3-fold or greater increase in LAT pro-
moter activity. Since this region lies downstream of the
transcription start sites, the effects observed could con-
ceivably be mediated at the level of transcription or a sub-
sequent step in the gene expression process, such as
mRNA stability or the efficiency of translation. However,
this region still possesses inhibitory activity when moved
upstream of the transcription start sites in the LAT pro-
moter (data not shown), suggesting that the effect occurs
at the level of transcription. Although the biological rele-
vance of the inhibitory region is presently unknown, the
fact that the magnitude of its activity varies between Jurkat
and RBL-2H3 cells suggests that it may modulate cell type
specific expression levels for the LAT gene.
Deletion analysis and linker scanning mutagenesis
revealed that the region from -390 to -350 was particularly
important for LAT promoter function. Within this region
we identified two Ets sites and demonstrated that these
sites bind the Ets transcription factor Elf-1. The finding
that the LAT gene is regulated by Elf-1 is consistent with
the known functions of Elf-1 and other members of this
transcription factor family. Ets proteins have been shown
to play a critical role in the development and function of
T cells as well as other cell types of the immune system
[25,26], and Elf-1 has been implicated in the regulation of
a number of genes expressed in cells of hematopoietic ori-
gin, including genes for the TCRζ chain, the CD4 co-
receptor, the immunoglobulin heavy chain, the cytokine
IL-2, and CD1D1 molecule [39-42]. The fact that both Ets
sites are 100% conserved in human, mouse, and rat (Fig.
1 and data not shown) also suggests that these sites play a
Elf-1 interacts with the -390 Ets site Figure 6
Elf-1 interacts with the -390 Ets site. A. A DNA probe 
encompassing the Ets site centered at -390 (-390 Ets wt) was 
labeled with 32P and incubated with nuclear extracts from 
Jurkat T cells in the absence or presence of 100-fold molar 
excess of competitor DNA. Samples were processed as 
described in the legend for Fig. 5. For competition experi-
ments, the unlabeled competitor DNA was the same 
sequence as that of the probe (self wt), the same sequence as 
the probe except containing point mutations within the Ets 
site (self mutEts), the consensus sequence for Ets family 
members (cons. wt) or the consensus sequence except for 
point mutations within the Ets site (cons. mutEts). The 
arrows indicates the specifically bound complex. B. Experi-
ments were conducted as in Fig. 5A except that the indicated 
antibody was added in place of competitor DNA.
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fundamental role in the regulation of LAT gene expres-
sion.
Adjacent to the Ets site centered at -360 we identified a
Runx site that is capable of binding Runx-1. Like the Ets
sites, this Runx site is 100% conserved in human, mouse,
and rat (Fig. 1 and data not shown). Similar to Ets, Runx
family members have been shown to be critical for hemat-
opoiesis and the expression of hematopoietic genes,
where they positively or negatively regulate gene expres-
sion depending on the context of their binding site and/or
prevailing intracellular conditions [30,31,43]. For exam-
ple, during T cell development and/or in mature T cells,
Runx family members positively regulate expression of
the interleukin-3, granulocyte macrophage-colony stimu-
lating factor, and TCR α and β genes [44-47] while they
inhibit expression of the CD4 gene [48].
A number of genes contain promoter or enhancer ele-
ments with adjacent Ets and Runx binding sites, including
the TCR α and β enhancers, the osteopontin promoter, the
immunoglobulin  µ heavy chain enhancer, and the
enhancers of the polyomavirus and the Moloney leuke-
mia virus [33,34,49-52]. Both Runx and Ets proteins con-
tain intramolecular inhibitory domains that can impede
DNA binding and studies have shown that Runx-1 and
certain members of the Ets family, namely Ets-1, MEF, and
NERF [32,34,36-38,53], can interact with each other, dis-
placing the inhibitory domains and thereby stimulating
DNA binding and transactivation. Elf-1 has also been
shown, at least in vitro, to be capable of interacting with
Runx-1 [32]. Based on these findings, and the close prox-
imity of the Ets and Runx sites within the LAT promoter,
we hypothesized that the Runx site would behave simi-
larly to the Ets site and contribute to the activation of LAT
gene expression. However, our results revealed that the
Runx site actually has a repressive effect on LAT promoter
activity, a result analogous to the inhibitory role of Runx
sites in the CD4 gene silencer region [30]. It is possible
that Runx-1 does not interact with Elf-1 at the LAT pro-
moter and thus no cooperative effects would be expected.
Consistent with this possibility, our EMSA data demon-
strate that Elf-1 and Runx-1 can independently bind their
respective sites in the LAT promoter (Fig. 9). Runx pro-
teins also interact with a number of other proteins that
influence whether they have a positive or negative effect
on gene expression [30,31,43]. Thus, Runx-1 may recruit
to the LAT promoter proteins that actively inhibit gene
expression. It is also possible that under different circum-
stances, for example during hematopoiesis or in other
cell-types, members of the Runx and Ets families coopera-
tively bind to the adjacent sites in the LAT promoter to
facilitate gene expression.
Our data from the analysis of LAT promoter activity in
various cell-types is intriguing. The lack of significant LAT
promoter activity in 70Z and Raji B cells, which do not
express the endogenous LAT gene, suggests that the pro-
moter region identified in this study may mediate cell-
type specific expression of this gene. However, other
mechanisms are likely to be involved in cell-type specific
expression since the LAT  promoter retains substantial
activity in HeLa cells, another cell line that fails to express
the endogenous gene [3]. In this latter situation, it is con-
ceivable that chromatin structure may play a more pre-
dominate role in cell-type specific regulation. It should
also be noted that since Elf-1 is expressed in B cells and
Overexpression of Elf-1 stimulates LAT promoter activity Figure 7
Overexpression of Elf-1 stimulates LAT promoter 
activity. The pGL3-basic reporter vector containing the -
400 to -1 wt region (wt) of the LAT promoter or the -400 to 
-1 region with point mutations within both Ets sites (mutEts) 
were transiently transfected into HeLa cells in the presence 
of the parental pCB6 vector or the expression vector for Elf-
1, pCB6-Elf-1. Twenty to twenty four hours later cells were 
harvested and fold activation was determined as described. 
The luciferase activity for each construct in the absence of 
co-transfected Elf-1 was then set at 1-fold. The resulted 
shown are the average fold induction and s.e.m. for at least 
three independent experiments. p < 0.05 for Elf-1 activation 
of the mutant promoter relative to that of wild-type as 
determined using the two-tailed t test.
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has been shown to activate gene expression in B cells
[39,54], it is unlikely that this transcription factor alone
plays a central role cell-type specific expression of LAT.
The results analyzing LAT promoter function in Jurkat and
RBL-2H3 cell lines, both of which express the endogenous
LAT gene [3], indicates that functional differences exist. In
particular, a promoter fragment spanning from -400 to -1
fails to support gene expression in the RBL-2H3 mast cell
line. One possible explanation of this result is that the Ets
sites do not exert a positive effect on gene expression in
mast cells. However, our data indicates that this is not the
case and instead points to another explanation, namely
that the -200 to -1 region and the Runx sites have a greater
suppressive effect in mast cells, and thereby may mitigate
any positive contribution made by factors binding to the
Ets sites. The results in RBL-2H3, Jurkat, and HeLa cells
also indicate that additional regulatory elements exist in
the region upstream of -400, and in particular in the
region spanning from -450 to -400. We have identified a
number of potential Sp-1 binding sites within this section
of the promoter and are currently exploring the role these
sites may play in LAT gene regulation (data not shown).
This and additional research will further elucidate the role
of various transcription factors in the regulation of LAT
gene expression, and should provide further insights into
the role each of these factors play in the cell-type specific
expression of this gene.
Conclusion
The goal of this study was to investigate the mechanisms
regulating transcription of the LAT  gene, which is
expressed in a number cell-types generated during hemat-
opoiesis. We have defined the proximal promoter region
and found binding sites for two families of transcription
factors, Runx and Ets, which are known to play important
roles in the development and function of hematopoietic
cells. These sites are capable of binding Runx-1 and Elf-1
and appear to have opposing effects on LAT promoter
function. These results provide initial insights into the reg-
ulation of the LAT gene and provide a framework for fur-
ther research.
Methods
Cell lines
All cell lines were obtained from the American Type Cul-
ture Collection. The Jurkat human acute Leukemia T cell
line, the 70Z/3.12 (70Z) mouse pre-B cell line, and the
Raji human lymphoblast-like B cell line were each grown
in RPMI-1640 media. The rat RBL-2H3 mast cell line and
the human HeLa epithelial cell line were grown in DMEM
media. All media was supplemented with 10% fetal calf
serum, penicillin, and streptomycin. The 70Z cell media
also contained 50 µM β-mercaptoethanol.
LAT promoter activity in various cell-types Figure 8
LAT promoter activity in various cell-types. A. 
Reporter constructs containing the indicated regions of the 
human LAT promoter were transiently transfected into the 
indicated cell-types. Following incubation, samples were har-
vested and after normalization to Renilla luciferase activity 
fold activation was calculated relative to that obtained with 
the promoterless pGL3-basic vector which was set at 1-fold. 
B. RBL-2H3 cells were transiently transfected with either the 
wild-type -1000 to -1 reporter plasmid or reporter plasmids 
containing the -1000 to -1 fragment with the indicated site(s) 
mutated. Following incubation, samples were harvested and 
after normalization to Renilla luciferase activity, the activity 
obtained with the wild-type promoter was set at 100%. p < 
0.05 for mutant reporters relative to wild-type using the 
two-tailed t test C. RBL-2H3 cells were transfected with the 
-1000 to -1 or -1000 to -200 reporter plasmids. Following 
incubation, samples were harversted, luciferase activities 
were measured and normalized to Renilla luciferase, and the 
activity obtained with empty pGL3-basic was set at 1-fold. 
For Fig. 8A-8C, the results shown are the average fold induc-
tion and s.e.m. from three or more independent experi-
ments. For 8B and 8C, p < 0.05 for the mutant reporters 
relative to wild-type as determined using the two-tailed t 
test.
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Plasmids
A pBAC plasmid containing the human LAT gene and the
surrounding genomic region was digested with NcoI and a
3543 bp DNA fragment extending approximately 3200 bp
upstream of the LAT translation start site was subcloned
into pBluescript KS II+ (Stratagene). This plasmid and
primers incorporating flanking KpnI and NheI restriction
sites were used in PCR to generate putative promoter frag-
ments that were then subcloned into KpnI  and  NheI
digested pGL3-Basic plasmid (Promega Corp.). This
placed the putative LAT promoter fragments immediately
upstream of the firefly luciferase gene in pGL3-Basic. For
linker scanning mutagenesis, sequential 10 bp mutations
incorporating a NotI restriction site were constructed as
follows: two fragments of the promoter region were gen-
erated by PCR. For one fragment (KpnI-NotI), the sense
primer at -1000 contained a flanking KpnI restriction site
while the anti-sense primer contained a NotI site spanning
the region to be mutated. For the second fragment, the
sense primer contained the NotI site and the anti-sense
primer at -1 contained a flanking NheI site. PCR products
were purified, then digested with KpnI and NotI or NotI
and NheI, and finally cloned into KpnI and NheI digested
pGL3-Basic.
Site-directed mutatgenesis of the putative Ets and Runx
DNA binding sites was conducted using the QuikChange®
II Site-Directed Mutagenesis kit (Stratagene). The specific
base pair changes were as follows: The Ets site centered at
-390 was changed from GATTTCCTGC to GATTTTTTGC,
the Runx site at -365 was changed from ACCACA to ATT-
ACA, and the Ets site centered at -360 was changed from
AGCTTCCTGC to AGCTTTTTGC. All plasmids created for
these studies were sequenced to ensure that unwanted
mutations were not incorporated during their construc-
tion.
The internal control pRL-TK Renilla lucifierase vector and
the pGL3-Control vectors were purchased from Promega
Corp. The expression vectors pCB6-Elf-1, along with the
parental pCB6 vector, were provided by Dr. Scott W. Hie-
bert, Vanderbilt University School of Medicine, Nashville,
Tennessee.
RLM-RACE
RNase Ligase-mediated Rapid Amplification of cDNA
ends (RLM-RACE) was performed using the FirstChoice®
RLM-RACE kit (Ambion, Inc). In this procedure, Poly(A)
RNA was isolated from Jurkat T cells using the PolyATtract
mRNA isolation System III (Promega Corp) and treated
with calf intestinal phosphatase to remove the 5' phos-
phate from truncated mRNA species. Tobacco acid pyro-
phosphatase treatment then removed the 5' cap structure
from full length RNA, followed by ligation of the 5' RACE
adaptor. Reverse transcription followed by two rounds of
PCR resulted in amplification of the 5' portion of the LAT
cDNA. PCR products were separated by agarose gel elec-
trophoresis, gel-purified, and cloned into pBluescript II
KS+ for DNA sequencing. A similar series of steps were
used to map the LAT transcription start sites using Human
Thymus RACE-Ready cDNA (Ambion, Inc.).
Transient transfection and Luciferase assay
Jurkat, RBL-2H3, and Raji cells were transiently trans-
fected by electroporation at 950 µF and either 240 V (Jur-
kat, Raji) or 300 V (RBL-2H3) using 1-5 × 106 cells, 2.5 µg
of pGL3 firefly luciferase reporter plasmid and 0.25 µg of
the internal control phRG-TK Renilla luciferase plasmid
per sample. HeLa cells were also transfected by electropo-
ration as described above except for experiments involv-
ing the overexpression of Elf-1, in which case 4 µg of the
parental pCB6 vector or Elf-1 expressing pCB6-Elf-1 was
included. For all tranfections, pBluescript II KS+ plasmid
DNA was also added to bring the final amount of DNA to
10 µg. 70Z cells were transfected using 2.5 × 105 cells, 0.9
µg of pGL3 reporter plasmid, 0.1 µg of phRG-TK plasmid,
and 3 µl of FUGENE 6 reagent (Roche Applied Science)
per sample according to the manufacturer's protocol. Fol-
lowing transfection, cells were resuspended in their
respective media, incubated 20–24 hr, then harvested and
assayed for firefly and Renilla luciferase activity using the
Dual-Luciferase Reporter Assay System (Promega Corpo-
ration). The ratio of firefly to Renilla luciferase activity was
calculated for each sample and the value obtained using
the promoterless pGL3-basic vector was set at one-fold
activation except for Elf-1 overexpression studies in HeLa
cells. In these experiments, the ratio of firefly to Renilla
luciferase activity obtained with the wild-type or mutEts
LAT reporter constructs and pCB6 was set at one-fold acti-
vation.
Duplicate or triplicate samples were included for all trans-
fections and the average and standard error of the mean
(s.e.m.) for each reporter plasmid or condition was calcu-
lated from three or more independent transfection exper-
iments using at least two preparations of each test
plasmid.
Preparation of nuclear extracts and the electrophoretic 
mobility shift assay
For the preparation of nuclear extracts, Jurkat T cells were
washed once with PBS, then lysed in a buffer containing
10 mM HEPES, pH 7.6, 60 mM KCl, 1 mM EDTA, 0.075%
NP-40, 1 mM DTT, 1 mM PMSF, 5 µg/ml each of apro-
tinin, leupeptin, and pepstatin. The resulting lysate was
centrifuged at 1500 rpm for 4 min and the nuclear pellet
washed once with lysis buffer lacking NP-40. The nuclear
pellet was then resuspended in nuclear extract buffer (20
mM Tris, pH 8.0, 400 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM PMSF, and 20% glycerol) and incubatedBMC Molecular Biology 2006, 7:4 http://www.biomedcentral.com/1471-2199/7/4
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on ice for 10 min. Centrifugation at 14 K rpm for 15 min
followed, and the protein concentration in the resulting
supernatant (nuclear extract) was determined by the Bio-
Rad DC Protein Assay prior to storage at -80°C.
The  32P labeled probes used in the electrophoretic gel
mobility shift assay (EMSA) were prepared by filling in
annealed oligonucleotides with the Klenow fragment of
DNA polymerase in the presence of [α-32P]dCTP and
other dNTPs followed by purification using NucTrap
probe purification columns (Stratagene). The sequence of
the probes used in EMSAs are as follows (mutations are
underlined): -390 wt : 5'-GCTTGATGATTTCCT-
GCCCTCGCC-3'; -390 mut Ets: 5;-GCTTGATGATTTTTT-
GCCCTCGCC-3'; -360 wt: 5'-
GGCACAGCTTCCTGCCGCAGGCC-3'; -360 mut Ets: 5'-
GGCACAGCTTTTTGCCGCAGGCC-3'; Runx/-360 Ets wt:
5'-GCGCTCACCACAGCTTCCTGCCGCAGG-3'; Runx/-
360Ets mutRunx: 5'-GCGCTCATTACAGCTTCCTGCCG-
CAGG-3'; Runx/-360Ets mutEts: 5'-GCGCTCAC-
CACAGCTTTTTGCCGCAGG-3'; Runx/-360Ets mutEts/
Runx: 5'-GCGCTCATTACAGCTTTTTGCCGCAGG-3'; con-
sensus Ets: 5'-GATCTCGAGCAGGAAGTTCGA-3'; consen-
sus mutEts: 5'-GATCTCGAGCAAGAAGTTCGA-3'. Note
that the GG at the 5' end of the -360 Ets probe and the ter-
minal C nucleotide at the 3' end were added to aid in 32P
labeling.
For EMSAs, 5 µg of nuclear extract was used in DNA bind-
ing reactions containing 10 mM HEPES, pH 7.6, 50 mM
KCl, 1 mM EDTA, 1 mM DTT, 5% glycerol, and 0.2 µg
sheared salmon sperm DNA. For competition experi-
ments a 100-fold molar excess of unlabeled competitor
DNA was also added, while for supershift experiments 1
µl of antibody was used. The Ets-1 (C-20), Ets-2 (H-140),
Elf-1 (C-20), Fli-1 (C-19), and Runx1 (N-20) antibodies
used in supershift experiments were purchased from Santa
Cruz Biotechnology, Inc. Samples were incubated on ice
for 15 min, 20 K cpm of labeled probe was then added,
and samples incubated an additional 30 min prior to
loading onto a 4.5% nondenaturing polyacrylamide gel.
Samples were electrophoresed at 4°C and 20 mA using a
0.5× TBE running buffer. After the separation of com-
plexes, the gel was dried and exposed overnight to Kodak
Biomax film at -80°C using an intensifying screen.
Accession numbers
The accession number for the human, mouse and rat DNA
sequences are: [GenBank:AC109460](human); [EMBL:
AJ438435](mouse); [EMBL: AJ001184] (rat).
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The transcription factor Runx1 binds to the LAT promoter Figure 9
The transcription factor Runx1 binds to the LAT pro-
moter. A. A DNA probe encompassing the Runx site and 
the Ets site centered at -360 (Runx/-360 Ets wt) was labeled 
with 32P and incubated with nuclear extracts from Jurkat T 
cells in the absence or presence of 100-fold molar excess of 
unlabeled competitor DNA. Samples were processed as 
described in the legend for Fig. 5. For competition experi-
ments, the unlabeled competitor DNA was the same 
sequence as that of the labelled probe (self wt), the same 
sequence as the probe except containing point mutations 
within the Ets site (self mutEts), the Runx site (self mutRunx) 
or both sites (self mutEts/Runx). B. Experiments were con-
ducted as in Fig. 9A, with the exception that the Elf-1 anti-
body was also added to the indicated sample. C. Experiments 
were conducted as described in Fig. 9A except that the 
Runx-1 antibody was added instead of unlabeled competitor. 
For A-C, the arrow denotes specific complexes. D. Jurkat 
and RBL-2H3 cells were transfected with the wild type -1000 
to -1 reporter plasmid or the -1000 to -1 reporter plasmid 
with a mutation within the Runx site. Following incubation, 
samples were harversted, luciferase activities were measured 
and normalized to Renilla luciferase, and the activity obtained 
with empty pGL3-basic was set at 1-fold. The results shown 
are the average fold induction and s.e.m. from three or more 
independent experiments. p < 0.05 for the mutant reporters 
relative to wild-type as determined using the two-tailed t 
test.
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